Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07262268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

StatusEnrolling by Invitation
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Jun 2026 to Nov 2026
    • Study completion pushed from Jul 2026 to Nov 2026
    v3
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2025 to Jan 15, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.
Trial Details
NCT Number NCT07262268
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions
(from sponsor)		 Familial Erythromelalgia
Related terms Channelopathies, Erythromelalgia, Generalized Epilepsy With Febrile Seizures Plus, 7, Neuralgia
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov